| Market Cap | 30.83M | P/E | - | EPS this Y | 4.90% | Ern Qtrly Grth | - |
| Income | -32.33M | Forward P/E | -1.01 | EPS next Y | 23.10% | 50D Avg Chg | -13.00% |
| Sales | - | PEG | 0.02 | EPS past 5Y | - | 200D Avg Chg | -40.00% |
| Dividend | N/A | Price/Book | 0.25 | EPS next 5Y | -65.60% | 52W High Chg | -65.00% |
| Recommedations | 1.70 | Quick Ratio | 13.88 | Shares Outstanding | 39.66M | 52W Low Chg | 10.00% |
| Insider Own | 0.07% | ROA | -25.80% | Shares Float | 28.89M | Beta | 0.89 |
| Inst Own | 46.06% | ROE | -70.71% | Shares Shorted/Prior | 83.33K/100.69K | Price | 1.37 |
| Gross Margin | - | Profit Margin | - | Avg. Volume | 137,261 | Target Price | 14.00 |
| Oper. Margin | - | Earnings Date | Nov 7 | Volume | 100,990 | Change | 5.38% |
Eledon Pharmaceuticals, Inc. operates as a clinical stage biotechnology company. The company uses its immunology expertise in targeting the CD40 Ligand (CD40L, also called CD154) pathway to develop therapies to protect transplanted organs and prevent rejection, and to treat amyotrophic lateral sclerosis (ALS). The company's lead compound in development is tegoprubart, an IgG1 and anti-CD40L antibody with high affinity for CD40 Ligand, a biological target with therapeutic potential. It is also developing its products for kidney transplantation, xenotransplantation, and liver transplantation. The company has a collaboration agreement with eGenesis, Inc. The company was formerly known as Novus Therapeutics, Inc. and changed its name to Eledon Pharmaceuticals, Inc. in January 2021. Eledon Pharmaceuticals, Inc. is headquartered in Irvine, California.